Business Wire

CURACLE and Théa Announce Licensing and Collaboration Agreement for the Development and Commercialization of Orally Administered Treatment for Diabetic Macular Edema and Wet-AMD

Share

CURACLE , a Korea-based biopharmaceutical company, today announced that it has entered into an exclusive license and collaboration agreement with Théa Open Innovation, the sister company of Théa, Europe’s number one independent ophthalmic company with a 150-year history, for the development and commercialization of CURACLE’s CU06-RE, that has the potential to become the first orally administered treatment for diabetic macular edema and wet age-related macular degeneration (wet-AMD).

Under the terms of the agreement, CURACLE will receive an upfront payment of $6 million and could receive up to an additional $157.5 million in potential development, regulatory and sales milestones, as well as royalties on sales if CU06-RE is successfully developed, which will entitle CURACLE to receive up to $2 billion in total payments. Théa and CURACLE will closely collaborate on the clinical development of this novel oral drug. CURACLE will be responsible for the Phase I and II clinical studies with TOI providing both financial and infrastructure support. Further, under the terms of the agreement, CURACLE will retain the marketing rights in all Asia countries while Théa will have the marketing rights in all other countries around the world.

According to Dr. Young Guen Kwon, the founder of CURACLE, “CU06-RE is expected to be the world’s first `orally administered' treatment for diabetic macular edema and wet-AMD, and because of its high efficacy and convenience as an oral treatment, CU06-RE promises to establish the standard for treatment that reduces the number of intraocular injection (IVT) administration made possible through co-administration with anti-VEGF.” Dr. Kwon added that “As the world’s first vascular endothelial dysfunction blocker developed with CURACLE’s SOLVADYS platform technology, CU06-RE can be applied to patients whose symptoms have worsened due to resistance to anti-VEGF injections, providing great hope for patients who currently do not have a suitable treatment option.”

”Through this strategic and collaborative alliance with Théa, a leading global ophthalmic company, we have been able to accelerate the development of CU06-RE as the world’s first oral treatment and the world’s first vascular endothelial dysfunction blocker,” said Jae Hyeon Ryu, the CEO of CURACLE. "We look forward to providing innovative treatments faster to the millions of patients with diabetic macular edema and wet-AMD around the world who are suffering without an appropriate treatment option,” added Mr. Ryu.

“We are excited about partnering with CURACLE, a truly innovative biotechnology company with a game changing technology platform,” remarked Mr. Jean-Frédéric Chibret, president of Théa. Mr. Chibret further commented that “through this licensing collaboration, Théa and CURACLE will provide a new first-in-class treatment with an alternative and non-invasive route of administration and most importantly, convenience for patients. This agreement is in line with the other partnerships that we have set up over the last two years and further illustrates our will to build a strong and diversified retina pipeline.”

About CURACLE

CURACLE (KOSDAQ) is a Korea-based clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics for the treatment of aged-related vascular and intractable metabolic diseases and cancers.

Founded in 2016, CURACLE has developed the disease-expressive screening system, SOLVADYS Platform, which screens substances that directly convert the pathological characteristics of the capillary vessels such as leakage, inflammatory activation, and apoptosis using human organ-specific primary endothelial cells. The SOLVADYS Platform dramatically improves the efficacy and ease of administration for acute and chronic conditions that are accompanied by vascular leakage, inflammation and loss of endothelial cells.

For more information visit: https://www.curacle.com

About Théa and Théa Open Innovation

Théa is a leading independent European pharmaceutical company specialized in the research, development, and commercialization of eye-care products.

Based in Clermont-Ferrand, France, this family-owned company has continued to expand by opening more than 30 affiliates and offices in Europe, Russia, North Africa, North and South America. Its products are available in 75 countries.

Théa Open Innovation (TOI) is a sister company of Théa. TOI's mission is to set up partnerships with companies and universities to help bring the most innovative products in ophthalmology to the market.

For more information visit: https://www.laboratoires-thea.com/en

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jeonghan Kim
CURACLE Co. Ltd
jeonghan.kim@curacle.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tensar to Be Acquired by Commercial Metals Company to Expand Leadership in Construction Solutions7.12.2021 15:30:00 EET | Press release

Tensar Corporation (“Tensar”), a global leader in geogrid engineered solutions for civil construction, and a portfolio company of Castle Harlan Inc.’s fund Castle Harlan Partners V, L.P., announced today it has entered into a definitive agreement to be acquired by Commercial Metals Company (NYSE: CMC) (“CMC”), as part of CMC’s strategy to expand its leadership in construction solutions. “I’m enthusiastic about the opportunity for Tensar to join with CMC for expanded reach in the civil infrastructure market,” said Mike Lawrence, CEO of Tensar. “Both companies have a rich history of innovation, service and commitment to our customers’ success. Together we will be well-positioned to grow into key markets, leveraging forthcoming infrastructure spending as well as growing requirements for more sustainable solutions globally. We look forward to tapping CMC’s innovative, advanced manufacturing expertise to bring powerful product and service benefits to our customers and partners. This is an e

BAI Announces 2021 Global Innovation Award Winners7.12.2021 15:30:00 EET | Press release

Today, BAI announced the 2021 winners for the BAI Global Innovation Awards, the industry’s most prestigious awards program, highlighting transformative solutions in financial services worldwide. This year’s winners were selected by the Innovation Circle, a panel of distinguished judges and advisors from around the world who are at the forefront of innovation. Together with BAI, they identified award finalists from an impressive list of submissions and eventually selected the winners and honorable mentions. Every year, BAI adjusts the award categories to align with the dynamic nature of the industry. A new category for 2021, Innovation in Digital Transformation, received the most nominations, reflecting the priority financial services leaders have placed on digital technology and improving the customer experience. “The commitment to innovation in the financial services industry increased again this year, with an even sharper focus on the customer,” said Debbie Bianucci, president and CE

SoftServe Acknowledged as a Major Contender in Healthcare Analytics Services by Everest Group7.12.2021 15:05:00 EET | Press release

SoftServe, a leading digital authority and consulting company, has been recognized by Everest Group as a Major Contender in healthcare analytics services, according to Everest Group’s Healthcare Analytics Services PEAK Matrix® Assessment 2022. The recognition marks the first year that SoftServe has participated in Everest Group’s annual assessment of the healthcare analytics services marketplace. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005472/en/ SoftServe Positioned as a Major Contender in Healthcare Analytics Services by Everest Group (Graphic: Business Wire) “Our positioning as a Major Contender in Healthcare Analytics is a validation of our strong healthcare domain and technology expertise and of our ability to accelerate business outcomes across the healthcare landscape,” said Adam Gabrault, Executive Vice President of Healthcare and Life Sciences at SoftServe. “We are thankful to our customers for their pa

Moody’s Recognized with CDP’s ‘A’ Score on Climate Action for Second Consecutive Year7.12.2021 15:00:00 EET | Press release

Moody’s Corporation (NYSE:MCO) announced today that it has received an ‘A’ score from CDP on climate action for the second consecutive year. The top score recognizes Moody’s as one of a small number of high-performing companies out of nearly 12,000 that are leading actions to cut emissions, mitigate climate risks and develop the low-carbon economy. “As a member of CDP’s Reporter Services and Supply Chain programs, Moody’s Corporation has demonstrated environmental leadership and commitment to curb climate change within their business, as well as among their suppliers. Looking ahead, we are excited to see their continued dedication to transparency and prolonged effort to securing a net-zero, sustainable world,” said Simon Fischweicher, Head of Corporates and Supply Chains for CDP North America. In 2021, Moody’s accelerated its commitment to achieve net-zero emissions by 2040, bringing its original target forward by ten years, and advanced its validated, interim net-zero science-based ta

Medicago and GSK Announce Positive Phase 3 Efficacy and Safety Results for Adjuvanted Plant-Based COVID-19 Vaccine Candidate7.12.2021 15:00:00 EET | Press release

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announce positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects, adults 18 years and above, across six countries. Vaccine efficacy was demonstrated in an environment dominated by SARS-CoV-2 variants, unlike most published Phase 3 efficacy trials for currently licensed COVID-19 vaccines that were conducted when only the ancestral virus was circulating, making direct comparisons impossible. The overall vaccine efficacy rate against all variants of SARS-CoV-2 was 71% (95% Confidence Interval: CI 58.7, 80.0; Per Protocol Analysis: PP). The corresponding number for people with an initial seronegative status indicating no previous exposure to COVID-19 was 75.6% (95% CI: 64.2-83.7; PP). The vaccine candidate demonstrated effi

Philip Morris International Receives Second Consecutive “Triple A” Rating from CDP7.12.2021 14:45:00 EET | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today, for the second year in a row, announced it has been recognized as a global environmental leader by CDP, a not-for-profit charity that runs a global disclosure system for investors, companies, cities, and regions to manage their environmental impacts. PMI has been honored by the CDP’s “Triple A” score, recognizing the company’s best-in-class environmental performance and leadership in tackling climate change, as well as protecting forests and water security. The ranking places PMI among the select few to achieve the prestigious Triple A score and among the world's most pioneering companies leading on environmental transparency and performance. “External validation from organizations like CDP encourages us to continue on our journey to create a net-positive impact on society. We are humbled PMI has received CDP’s ‘Triple A’ distinction for a second time,” said Jennifer Motles, Chief Sustainability Officer. “As we continue to transf

Alvotech and Oaktree Acquisition Corp. II Announce Merger Agreement to Create a Leading Publicly-Traded Global Biopharmaceutical Company7.12.2021 14:00:00 EET | Press release

Alvotech Holdings S.A. (“Alvotech”), a leading global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II (NYSE: OACB.U, OACB, OACB WS), a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, L.P. (“Oaktree”), announced today that they have entered into a definitive merger agreement. Upon completion of the transaction, the combined company’s securities are expected to be traded on NASDAQ under the symbol “ALVO.” Company Overview Alvotech, founded in 2013 in Reykjavik, Iceland, is a vertically integrated platform company focused exclusively on developing and manufacturing biosimilar medicines for the global market. Alvotech has a world class management team of proven and highly experienced pharmaceuticals executives with deep expertise in biologics and biosimilars, led by a visionary founder, Robert Wessman, who has a track record of building g

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom